CBD and autoimmune diseases - a review of studies and inflammatory conditions

Autoimmune diseases affect about 5-8% of the population in Western countries - it is estimated that over 400 million people worldwide suffer from them (Jacobson et al., Clinical Reviews in Allergy & Immunology, 2007). CBD, acting as a modulator of the endocannabinoid system and exhibiting anti-inflammatory properties in numerous preclinical studies, is generating increasing interest in this group of disorders. This article presents current scientific data - with key caveats regarding the level of evidence and safety of CBD use by individuals treated with immunosuppressants.

KEY INFORMATION
• CBD inhibits pro-inflammatory cytokines TNF-α, IL-6, and IL-1β in in vitro and animal models - a mechanism biologically justified in autoimmunity.
• No autoimmune disease has an approved treatment with CBD alone - existing data are mainly preclinical.
• CBD may interact dangerously with immunosuppressive drugs (methotrexate, cyclosporine, tacrolimus) by inhibiting CYP3A4.
• WHO (2018) assessed the safety profile of CBD as good, but hepatotoxicity was observed at high doses (as in Epidiolex).
• The best-studied areas: RA, MS, Crohn's disease, SLE, psoriasis - all still at the preliminary clinical level.

Key figures - what studies say about CBD and autoimmunity

Before we delve into the mechanisms, it is worth looking at the hard numbers from published studies. The table below collects the most important statistical data from studies on CBD and inflammatory/autoimmune diseases.

The mechanism of action of CBD in inflammatory conditions - what happens at the cellular level

Autoimmune diseases are driven by an improperly activated immune system that attacks the body's own tissues - joints in RA, myelin sheaths in MS, intestines in Crohn's disease. CBD interacts with several important pathways regulating this process.

First: inhibition of pro-inflammatory cytokines. Cytokines are protein chemical signals that coordinate the inflammatory response. In autoimmune diseases, TNF-α, IL-6, and IL-1β are produced in excess, driving tissue destruction. In vitro studies have shown that CBD inhibits the secretion of these cytokines by macrophages and dendritic cells - structures crucial for initiating and maintaining inflammation (Nagarkatti et al., Future Medicinal Chemistry, 2009).

Second: activation of PPAR-γ receptors. CBD is an agonist of nuclear PPAR-γ receptors (Peroxisome proliferator-activated receptor gamma) - proteins that regulate the expression of genes related to inflammation and metabolism. Activation of PPAR-γ has anti-inflammatory and immunomodulatory effects, which may explain some of CBD's effects in models of inflammatory bowel diseases.

Third: modulation of T cells. In autoimmune diseases, maintaining regulatory T cells (Treg) is critical - cells that suppress excessive immune responses. Animal studies suggest that CBD may promote the differentiation of Treg at the expense of pro-inflammatory Th17 cells. This mechanism is particularly interesting in the context of diseases such as MS or SLE (Turcotte et al., PLOS ONE, 2010).

CBD in specific autoimmune diseases

Rheumatoid Arthritis (RA)

RA is a chronic inflammatory joint disease affecting about 1% of the adult population. The study by Blake et al. from 2006, published in Rheumatology, is one of the few randomized controlled trials with cannabinoids in RA. Sativex (a combination of THC and CBD) was evaluated over 5 weeks - the results showed a statistically significant reduction in pain at rest, pain on movement, and morning stiffness of the joints (Blake et al., Rheumatology, 2006). Important note: Sativex contains THC and CBD in a 1:1 ratio - conclusions from this study cannot be directly applied to CBD alone.

Multiple sclerosis (MS)

MS is an autoimmune disease that destroys the myelin sheaths of neurons. For MS, Sativex (THC+CBD) is registered for the treatment of spasticity resistant to other medications. This drug is available in Poland by prescription. CBD alone without THC has less documented effects in MS - preclinical studies indicate neuroprotective effects and inhibition of neuroinflammation, but there is a lack of large RCTs with CBD alone.

Crohn's disease and ulcerative colitis

An open study by Naftali et al. (2011) evaluated cannabinoids in 13 patients with treatment-resistant Crohn's disease. After 3 months of therapy, 10 out of 13 patients achieved clinical remission, and the mean disease activity score (CDAI) dropped from 330 to 152 (Naftali et al., Isr Med Assoc J, 2011). Note: open study without a control group - the placebo effect is significant. Later RCT (Naftali 2013) with CBD alone did not show a significant difference vs placebo, suggesting that earlier effects may have been partially related to THC.

Systemic lupus erythematosus (SLE)

SLE is a severe autoimmune disease affecting multiple organs. Studies on CBD in SLE are mainly preclinical data and survey analyses. A survey study by Gruber et al. (2021) conducted among 200 SLE patients showed that 38% use some form of cannabinoids, primarily for pain relief and improving sleep - but there is a lack of controlled clinical studies in this group.

CBD and psoriasis and atopic dermatitis

Psoriasis and atopic dermatitis (AD) are inflammatory diseases with a significant autoimmune component. The skin has its own local endocannabinoid system - the presence of CB1, CB2, and TRPV1 receptors on keratinocytes, fibroblasts, and skin immune cells is well documented (Bíró et al., Trends in Pharmacological Sciences, 2009). This opens potential applications for CBD both orally and topically (creams, balms) in dermatological diseases with an inflammatory background.

In psoriasis, we deal with excessive proliferation of keratinocytes driven by pro-inflammatory cytokines - primarily IL-17 and TNF-α. In vitro studies have shown that CBD inhibits keratinocyte proliferation and reduces cytokine secretion in an in vitro psoriasis model (Wilkinson & Williamson, Journal of Dermatological Science, 2007). In AD, the key factor is the saturation of Th2 cytokines (IL-4, IL-13, IL-31), which drive inflammation and itching - studies suggest that CBD and other cannabinoids may modulate the Th2 response.

An important difference compared to other autoimmune diseases: in skin diseases, it is possible to use CBD topically - without the risk of systemic interactions with immunosuppressive drugs. CBD creams and ointments are not absorbed sufficiently to achieve blood concentrations capable of inhibiting CYP3A4. This is a significant practical advantage for patients with psoriasis or AD who are simultaneously undergoing biological therapy or methotrexate.

Unresolved questions and the future of research

Research on CBD in autoimmune diseases is entering a new phase. Several active or recently completed studies evaluating CBD in RA, SLE, and inflammatory bowel diseases are registered on the ClinicalTrials.gov portal. The biggest barrier to progress is the legal status of CBD in many countries (which complicates research funding), the lack of standardization of dosing and products, and the difficulty in recruiting patients who are already under specialist care and using disease-modifying medications.

In our observation, patients with autoimmune diseases often report improved sleep quality and reduced subjective pain after starting CBD - which is consistent with the best-documented properties of CBD. It is less certain whether CBD directly affects disease activity (the number of flares, laboratory results, the number of swollen joints) - as this requires long, controlled studies that are still lacking.

Key questions that science still needs to answer: what is the optimal dose of CBD for specific autoimmune diseases, are the effects of CBD additive with biological drugs, how long should CBD be used before assessing efficacy, does full-spectrum CBD work better than isolate in the context of immunomodulation, and what are the long-term immunological consequences of regular CBD supplementation.

Critical assessment of evidence - what is known and what is not known

A fair assessment of the state of research on CBD in autoimmune diseases requires distinguishing levels of scientific evidence. The hierarchy of evidence - from strongest to weakest - is as follows: systematic reviews of RCTs > single RCTs > cohort studies > open-label studies > animal studies > in vitro studies.

Most data on CBD in autoimmunity comes from in vitro studies and animal models - the weakest level of evidence. Extrapolating results "CBD inhibits TNF-α in a macrophage cell line" to "CBD will help a patient with RA" is methodologically unjustified. In vitro biology and the biology of the human body with its complex pharmacokinetics, microbiome, and genetic variability are entirely different systems.

The third methodological issue: many studies on CBD and inflammatory conditions in vitro use CBD concentrations that are unattainable in vivo with reasonable oral dosing. CBD has low oral bioavailability (about 6-19% at typical oral doses) - which means that CBD concentrations in inflamed tissues may be several times lower than those used in cell studies. This is a key limitation that makes extrapolating in vitro results to clinical dosing methodologically risky.

The paradox of CBD in autoimmunity is that the immunomodulation mechanism is a double-edged sword: a substance that suppresses the immune system can alleviate autoaggression but simultaneously increase susceptibility to infections. Most immunosuppressive drugs used in autoimmunity (methotrexate, azathioprine, steroids) have this risk profile. It is unknown whether CBD, with regular use, will produce a similar, clinically significant immunosuppressive effect in humans - clinical studies simply have not evaluated this.

Safety of CBD with immunosuppressive drugs - key interactions

This is the most important practical aspect for patients with autoimmune diseases considering CBD. Most immunosuppressive drugs used are metabolized by cytochrome P450 enzymes - and CBD is an inhibitor of these enzymes. This means that CBD may raise the concentration of these drugs in the blood to potentially toxic levels (Brown & Winterstein, Pharmacy, 2019).

Immunosuppressive drugs with a high risk of interactions with CBD: cyclosporine (CYP3A4 substrate - CBD may drastically increase its concentration, leading to nephrotoxicity), tacrolimus (similar mechanism to cyclosporine), methotrexate (complex metabolism, CBD may disrupt its renal excretion), mycophenolate mofetil, azathioprine. Even if a doctor approves the use of CBD, monitoring drug concentrations in the blood is necessary after starting supplementation.

Frequently Asked Questions

Can CBD help with autoimmune diseases?

Preclinical studies suggest that CBD may modulate the immune response - inhibiting pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and NF-κB activation. However, no autoimmune disease has an approved treatment with CBD alone. Existing clinical data are preliminary and involve small patient groups or studies without a control group. CBD does not replace immunosuppressive medications prescribed by a rheumatologist or immunologist.

Can CBD interact with immunosuppressive drugs?

Yes - this is a serious safety issue. CBD inhibits CYP3A4 and CYP2D6 enzymes that metabolize, among others, cyclosporine, tacrolimus, and methotrexate. Inhibition of these enzymes may increase drug concentrations to toxic levels (Brown & Winterstein, Pharmacy, 2019). Always consult with your attending physician before starting CBD and monitor drug concentrations.

Which autoimmune diseases are best studied in the context of CBD?

The best clinically studied (though still preliminary): RA - where Sativex (THC+CBD) showed efficacy in RCT (Blake et al., 2006), MS - where Sativex is registered for the treatment of spasticity, Crohn's disease - mixed results in two Naftali studies. SLE and psoriasis have mainly observational and preclinical data. There are no large RCTs with CBD alone in any autoimmune disease.

How does CBD affect cytokines and inflammation?

CBD inhibits the production of TNF-α, IL-6, and IL-1β by macrophages and dendritic cells (Nagarkatti et al., Future Medicinal Chemistry, 2009), activates PPAR-γ receptors (anti-inflammatory action), inhibits NF-κB activation, and may promote the differentiation of regulatory T cells. These mechanisms are proven in vitro and in animal models - clinical translation in humans requires further RCTs.

Is CBD safe for autoimmune diseases?

WHO (2018) assessed the safety profile of CBD as good in the general population. In autoimmune diseases, specific risks arise: interactions with immunosuppressive drugs, hepatotoxicity at high doses (observed in Epidiolex studies - typically above 20 mg/kg/day), and uncertainty regarding the long-term impact on the immune system. If you are taking immunosuppressive drugs - mandatory consultation with a doctor before using CBD.

This article is for informational and educational purposes and does not replace consultation with a doctor. If you are pregnant, breastfeeding, taking medications, or have chronic conditions, consult the use of supplements or herbs with a specialist.

Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-05-04